Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.81
- Piotroski Score 6.00
- Grade Neutral
- Symbol (ALKS)
- Company Alkermes plc
- Price $27.66
- Changes Percentage (4.14%)
- Change $1.1
- Day Low $26.76
- Day High $27.69
- Year High $32.88
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/23/2024
- Fiscal Year End N/A
- Average Stock Price Target $35.00
- High Stock Price Target $50.00
- Low Stock Price Target $27.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $3.36
- Trailing P/E Ratio 7.12
- Forward P/E Ratio 7.12
- P/E Growth 7.12
- Net Income $355.76 M
Income Statement
Quarterly
Annual
Latest News of ALKS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
British government had 'constructive' talks with Musk's X over disinformation, minister says
The UK government has engaged in talks with Elon Musk's social media platform X regarding misinformation and harmful content. Minister Kyle emphasized constructive discussions with all major social me...
By CNBC | 14 hours ago -
Sony in talks to buy Pink Floyd music rights for about $500 million, FT reports
Sony Music is in advanced negotiations to acquire the music rights of Pink Floyd for around $500 million. The deal has been hindered by internal conflicts within the band, particularly between Roger W...
By Yahoo! Finance | 16 hours ago -
Sam Altman tells Oprah he talks about AI with someone in government every few days
OpenAI's founder, Altman, emphasizes the need for government partnerships to ensure AI safety. The company collaborates with the government to establish safety testing and regulatory frameworks, aimin...
By Business Insider | 22 hours ago
